Clinical

The financial aftereffects of cancer have a tremendous impact on young adults as they move forward with their lives after treatment.

Updates on FDA approvals and extended indications for oncology drugs.

Evaluation of Prosigna's risk of relapse score as a predictor of response to multiagent neoadjuvant chemotherapy in HR+/HER2 breast cancer patients.

An update on recent progress in oncology managed care.

The American Society of Clinical Oncology has issued a statement asking for an improved evidence base for treating older adults with cancer.

A new study, published in JAMA Oncology has identified a widespread gap in counseling services for patients who undergo BRCA testing.

A study presented at the European Society of Cardiology meeting has found that cancer increases cardiac stress, which is further accentuated by chemotherapy.

Pathways are still a young enterprise so barriers to their adoption are being more readily recognized than the number of problems being solved are, according to Robert Dubois, MD, PhD, chief science officer and executive vice president of the National Pharmaceutical Council.

Stand Up 2 Cancer, in collaboration with the American Association for Clinical Research, will be funding innovative research grants with a potential to further translational cancer research.

Adolescent and young adult cancer patients face multiple barriers to ensuring adequate care: from unsure providers to financial constraints. Improved care coordination and recognition of the needs of this population can lead to much improved outcomes.

Evidence-Based Oncology spoke with Rajen Mody, MBBS, from the University of Michigan Health System, about his experiences treating young cancer patients, the survivorship program offered by the University of Michigan, and next generation sequencing.

Changes in the healthcare marketplace are steadily pushing changes for physicians and specialty practices of all kinds. Blaming the 340B drug discount program is both misleading and unproductive.

The new test, developed by Dako, will provide information on the survival benefit of patients with non-squamous NSCLC treated with nivolumab.

A new study published in JAMA Oncology has identified disparate survival outcomes across sites of care.

The PD-1 inhibitor antibody was approved by the FDA for use in patients who have progressed on platinum-based treatment.

With the final guidance expected in November, UK will follow Europe in the use of pembrolizumab in treating advanced melanoma patients refractory to previous treatment as well as those who have not been previously treated.

A new study published in the journal BMJ Innovations that surveyed doctors and nurses in the United Kingdom has found routine breach of patient privacy through the use of digital devices.

Through a multi-site, multidisciplinary approach, AYA@USC addresses the unique needs of young adult cancer patients, improving outcomes and bridging the care gap in this population.

Many individuals with chronic obstructive pulmonary disease (COPD) are only diagnosed after they experience late-stage exacerbations, but a new tool could hasten the process of diagnosing cases of COPD.

Adolescent and young adults (AYA) constitute a distinct population amongst patients with cancer. Historically, AYA patients with ALL treated along pediatric-inspired protocols had better outcomes compared to those treated on standard "adult type" regimens.

My role as a patient was simple-accept the suffering I had to endure. But it becomes hard to find the line between when to suffer and when to question.

Steven Rosenberg, MD, chief of surgery at NCI's Center for Cancer Research, has been awarded the 2015 Samuel J. Heyman Service to America Medal, or Sammie for his contributions to the field of immune-based cancer treatments.

A retrospective follow-up in women who had received grafts of cryopreserved ovarian tissue discovered a 30% success rate in bearing a child.

Tumors caught early have a lower probability of advancing to the lymph nodes and improve patient outcomes, the BMJ study found.

A missed opportunity in cancer care, according to Joseph Alvarnas, MD, is the use of age-adapted treatment strategies for adolescent and young-adult patients (AYA).

The PD-L1 inhibitor was granted orphan drug status just last month.

Price transparency continues to plague healthcare, as this new report from Castlight Health suggests.

As HIV-infected adults live longer, they are increasingly susceptible to specific cancer types. This calls for targeted cancer prevention efforts in this population.

A discussion on the challenges of implementing standards for addressing fertility risks associated with cancer and its treatment and describes an interactive training for healthcare providers to help them overcome challenges to implementation.

Suggestions on how to approach a childhood cancer survivor in your practice, several useful resources, and information on what referrals and tests may be indicated.